Editorial|Volume 14, Issue 14|pp 5612—5613

Metformin and breast cancer: an opportunity for pharmacogenetics

Elisabet Cuyàs¹, Begoña Martin-Castillo², Javier A. Menendez¹

¹Metabolism and Cancer Group, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology–Girona Biomedical Research Institute, Girona, Spain
²Clinical Research Unit, Catalan Institute of Oncology–Girona, Girona, Spain

* On behalf of the METTEN study group

Received: June 7, 2022Accepted: July 11, 2022Published: July 18, 2022

https://doi.org/10.18632/aging.204180

Copyright: © 2022 Cuyàs et al.This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.